Yamo Pharmaceuticals

Cutting Edge Pharmaceutial Technologies

Board of Directors

Chuck Bramlage

  • Launched 28 products in 15 therapeutic areas
  • CEO of Pearl Therapeutics from 2011-2016 which was sold in 2013 to Astra Zeneca for $1.1B.
  • Previously COO of Pharmaceutical Products at Covidien, President of European operations at Valeant and President and CEO of Battelle Pharma, various commercial positions of increasing responsibility at Merck and GSK.

Steve Hoffman

  • Steve Hoffman is the Inventor of L1-79 and Co-Founder of Yamo Pharmaceuticals.  
  • Mr. Hoffman is a biotechnology entrepreneur with more than two decades of experience founding and leading life-sciences companies focused on novel therapeutic approaches. 
  • Previously, Mr. Hoffman was a Co-Founder, Chairman, President, and Chief Executive Officer of Tyme Technologies, Inc., a publicly traded biotechnology company that pursued metabolism-based therapeutic strategies in oncology. During his tenure, he led the company through multiple stages of clinical development and the public markets.
  • Mr. Hoffman has devoted his career to advancing innovative, mechanism-driven therapies in areas of high unmet medical need. 
  • As a member of Yamo’s Board of Directors, he brings deep institutional knowledge of the company’s scientific foundations, long-term strategic vision, and experience navigating clinical development and regulatory pathways.

Andrew Intrater

  • In 2019, Mr. Intrater founded and continues to manage FEA Innovations LLC, a family office focused on exploring investment opportunities in early to growth stage technology companies, both as control and syndicate investor.
  • Previously, Mr. Intrater was the Chief Executive Officer of Columbus Nova, also known as Sparrow Capital Holdings, LLC, a multi-strategy investment firm he founded in 2000. In his role with Columbus Nova, Mr. Intrater managed over $2 billion of assets under management, including active and passive investments in private equity, venture capital and real estate across a wide variety of industries. 
  • Mr. Intrater served as a Managing Member of CNMB, a real estate investment management, financial advisory and alternative asset platform and co-founded CNTP, a global, multi-stage, technology investment firm.
  • Mr. Intrater’s current board memberships include Eccentex Corporation and nuPSYS Inc.. He is also currently on the executive committees of the USC Shoah Foundation and the Auschwitz-Birkenau Museum Foundation. Mr. Intrater was previously on the boards of CIFC Corp., DeepCube Ltd., Cyalume Technologies, Inc. and Rhapsody International Inc., and served on the advisory committees of Core Capital Partners, RSV Venture Partners and i2BF Global Ventures.
  • In 1985 Mr. Intrater founded ATI, the predecessor of Oryx Technology Corp. Mr. Intrater served Oryx as President and Chief Operating Officer until 1999, as it grew into a leading manufacturer of semiconductor test equipment. While at Oryx he led its 1994 IPO and oversaw two strategic acquisitions, including the purchase of Zenith’s power converter division. He also introduced a transportable, secondary ion mass spectrometer to QA groups in the hard disk and magnetic read/write head markets.
  • Mr. Intrater holds a B.S. in Chemical Engineering from Rutgers University and performed graduate studies in Materials Science at Columbia University.

John McShane

  • John McShane’s previous roles include as the Executive Vice President & General Counsel of Philadelphia Energy Solutions and as Executive Vice President and General Counsel of Global Crossing, a telecommunications company, as well as Chairman of Global Crossing UK.
  • As General Counsel, Mr. McShane oversaw and managed all of Global Crossing’s legal matters and, prior to his appointment as General Counsel, he served as Assistant General Counsel. In this role, he led the negotiations of network infrastructure agreements for the build-out of the Pan European Crossing network.
  • Prior to joining Global Crossing, Mr. McShane spent 12 years at several international law firms, including positions as an Associate at Simpson Thacher & Bartlett from 1987 through 1996 and as Senior Counsel at Shearman & Sterling, Cadwalader, Wickersham & Taft, and Brown & Wood, where his main focus was on representing major commercial banks, financial institutions and corporations in connection with a broad range of their corporate, commercial and financing activities.
  • Mr. McShane holds a JD cum laude from Harvard Law School and a BA in Liberal Arts from St. John’s College. He is admitted to the New York State Bar.

Pete Meyers

  • Pete Meyers has been a Non-Executive Director of Yamo since October 1, 2024.
  • Mr. Meyers was the Chief Financial Officer of Slayback Pharma LLC, a KKR portfolio company, until Slayback was sold to Azurity Pharmaceuticals, Inc. Prior to joining Slayback, Mr. Meyers served in Chief Financial Officer roles at Eagle Pharmaceuticals, Inc., Motif BioSciences Inc. and TetraLogic Pharmaceuticals Corporation.
  • Prior to his role at TetraLogic, Mr. Meyers spent 18 years in health care investment banking, holding positions of increasing responsibility at Dillon, Read &Co., Credit Suisse First Boston LLC and, most recently, as Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc.
  • Mr. Meyers also serves on the Board of Immutep Limited (NASDAQ: IMMP; ASX: IMM). He is the Chairman and President of The Thomas M. Brennan Memorial Foundation, Inc., and he is also the Vice Chairman of East End Hospice, Inc. He earned a Bachelor of Science degree in Finance from Boston College and a Master of Business Administration degree from Columbia Business School.

Ashok Srinivasan

  • Board member of Yamo Pharmaceuticals since 2021, appointed following the Autism Impact Fund’s investment supporting Yamo’s autism program.
  • Chief Scientific Officer of the Autism Impact Fund and the nonprofit Lipedema Foundation, applying a patient-oriented, translational approach to therapeutic development.
  • Spent seven years at the NSABP Foundation / NRG Oncology, translating scientific advances into clinical trials and contributing to the rationale for 10+ oncology studies.
  • Former NGS Facility Director at the University of Pittsburgh and Staff Scientist at the NIH (NHLBI), with leadership experience across academia and government research.
  • Holds a PhD in Molecular Biology from the University of Pittsburgh; completed postdoctoral training at Harvard Medical School and Massachusetts General Hospital.
  • Author or co-author of 20+ peer-reviewed publications, with a focus on precision medicine and data-driven therapeutics.